Safety and Efficiency of the PacePress to Prevent Hemorrhagic Complications in Patients Undergoing CIED Implantation. (PacePress)
Assessment of Safety and Efficiency of the Medical Device Called PacePress to Prevent Hemorrhagic Complications in Patients With High Bleeding Risk Undergoing CIED Implantation Procedures in an Open-label, Multi-Centre Clinical Trial.
Sponsor: Medinice S.A.
Terminated
The study was stopped at interim analysis due to significantly better outcomes with PacePress, consistent with the predefined statistical methodology.
Other Hematoma trials with similar outcome
Listed as NCT05292326, this NA trial focuses on Hematoma and Hemorrhage and remains terminated or withdrawn. Sponsored by Medinice S.A., it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2025 — Oct 2025 [monthly]
Recruiting NA
-
Oct 2024 — Sep 2025 [monthly]
Recruiting NA
-
Sep 2024 — Oct 2024 [monthly]
Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Recruiting NA
Status: Unknown → Recruiting
▶ Show 5 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Feb 2023 — Apr 2024 [monthly]
Recruiting NA
-
Dec 2022 — Feb 2023 [monthly]
Recruiting NA
-
Apr 2022 — Dec 2022 [monthly]
Recruiting NA
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medinice S.A.
For direct contact, visit the study record on ClinicalTrials.gov .